1. Home
  2. KOS vs SNDX Comparison

KOS vs SNDX Comparison

Compare KOS & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kosmos Energy Ltd. (DE)

KOS

Kosmos Energy Ltd. (DE)

HOLD

Current Price

$3.26

Market Cap

1.6B

Sector

Energy

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$19.92

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOS
SNDX
Founded
2003
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.9B
IPO Year
2011
2014

Fundamental Metrics

Financial Performance
Metric
KOS
SNDX
Price
$3.26
$19.92
Analyst Decision
Hold
Strong Buy
Analyst Count
6
13
Target Price
$1.91
$38.69
AVG Volume (30 Days)
17.3M
1.5M
Earning Date
05-05-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
11.56
EPS
N/A
N/A
Revenue
$1,288,352,000.00
$172,352,000.00
Revenue This Year
$27.11
$107.19
Revenue Next Year
N/A
$41.88
P/E Ratio
N/A
N/A
Revenue Growth
N/A
627.84
52 Week Low
$0.84
$8.59
52 Week High
$3.32
$25.59

Technical Indicators

Market Signals
Indicator
KOS
SNDX
Relative Strength Index (RSI) 68.25 36.08
Support Level $1.62 $19.46
Resistance Level N/A $22.33
Average True Range (ATR) 0.15 1.09
MACD 0.05 -0.41
Stochastic Oscillator 95.74 16.23

Price Performance

Historical Comparison
KOS
SNDX

About KOS Kosmos Energy Ltd. (DE)

Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: